Bioventrix launches quarterly newsletter on Less Invasive Ventricular Enhancement

October - December 2015

Updated clinical results of 71 Patients confirm efficacy and durability

Bioventrix launches quarterly newsletter on Less Invasive Ventricular Enhancement

BioVentrix, Inc announces the first Quarterly Newsletter presenting updates and overall results of Less Invasive Ventricular Enhancement. 

Clinical trials now involve 10 implanting centers in 5 countries - Italy, France, Czech Republic, Spain, and Germany. 
The 30th hybrid transcatheter procedure with the Revivent-TC™ system was completed last month.  
The data continues to show the same volume reduction efficacy with this hybrid approach as was demonstrated with the surgical technique. 
August also marked the 5th anniversary of the first Revivent™ human implant and the long term durability is confirmed. 
The therapy is helping many ischemic heart failure patients who have few remaining therapeutic options.   

To read the full newsletter, click HERE.  
« Go back